Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?

References

• Levin RJ, Both S, Georgiadis J, et al. The physiology of female sexual function and the pathophysiology of female sexual dysfunction (Committee 13A). J Sex Med. 2016;13(5):733–759.
   PubMed Web of Science ®Google Scholar
• Brotto L, Atallah S, Johnson-Agbakwu C, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2016;13(4):538–571.
   PubMed Web of Science ®Google Scholar
• McCabe MP, Sharlip ID, Lewis R, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 2016;13(2):153–167.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstetrics and Gynecology. 2008;112(5):970–978.
   PubMed Web of Science ®Google Scholar
• Rubin ES, Rullo J, Tsai P, et al. Best practices in North American pre-clinical medical education in sexual history taking: consensus from the summits in medical education in sexual health. J Sex Med. 2018;15(10):1414–1425.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Hahn SR, Goldstein SW, et al., The international society for the study of women’s sexual health process of care for the identification of sexual concerns and problems in women. Mayo Clin Proc. 94(5): 842–856. 2019.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Cottler-Casanova S, Clayton AH, et al. The evolution of the female sexual disorder/dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD. Sex Med Rev. 2021;9(1):36–56.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Sand M, Balon R, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions-part i. J Sex Med. 2016;13(12):1881–1887.
   PubMedGoogle Scholar
• Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions-part ii. J Sex Med. 2016;13(12):1888–1906.
   PubMedGoogle Scholar
• Parish SJ, Meston CM, Althof SE, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part iii. J Sex Med. 2019;16(3):452–462.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Gardella B. What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions? Expert Opin Pharmacother. 2019;20(7):777‐9.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric. 2013;16 Suppl 1(sup1):25–30.
   PubMedGoogle Scholar
• Farmer M, Yoon H, Goldstein I. Future targets for female sexual dysfunction. J Sex Med. 2016;13(8):1147–1165.
   PubMed Web of Science ®Google Scholar
• Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol. 2018;132(2):453–458.
   PubMed Web of Science ®Google Scholar
• Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735‐8.
   Web of Science ®Google Scholar
• Jannini EA, Nappi RE. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. 2018;6(3):384–395.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother. 2015;16(6):875‐87.
   Web of Science ®Google Scholar
• Kingsberg SA, Althof S, Simon JA, et al. female sexual dysfunction-medical and psychological treatments, committee 14 [published correction appears in J sex med 2018;15:270]. J Sex Med. 2017;14:1463‐91.
   Web of Science ®Google Scholar
• Clayton AH, Kingsberg SA, Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex Med. 2018;6(2):59–74.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, et al. Addressing vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019;10:561.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Simon JA. Female hypoactive sexual desire disorder: a practical guide to causes, clinical diagnosis, and treatment. J Womens Health (Larchmt). 2020;29(8):1101–1112.
   PubMed Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an international menopause society white paper. Climacteric. 2018;21(5):415–427.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: international Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–128.
   PubMed Web of Science ®Google Scholar
• Goldstat R, Briganti E, Tran J, et al. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003;10(5):390–398.
   PubMed Web of Science ®Google Scholar
• Davis SR, Baber R, Panay N, et al., Global consensus position statement on the use of testosterone therapy for women. Climacteric. 22(5): 429–434. 2019.
   PubMed Web of Science ®Google Scholar
• Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2021;18:1–9.
   Google Scholar
• Nappi RE, Cucinella L, Martini E, et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22(3):289–295.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Di Ciaccio S, Genazzani AD. Prolactin as a neuroendocrine clue in sexual function of women across the reproductive life cycle: an expert point of view. Gynecol Endocrinol. 2021;37(6):490–496.
   PubMed Web of Science ®Google Scholar
• Carter CS. The Oxytocin–Vasopressin pathway in the context of love and fear. Front Endocrinol (Lausanne). 2017 Dec 22; 8:356
   PubMed Web of Science ®Google Scholar
• Cera N, Vargas-Cáceres S, Oliveira C, et al. How relevant is the systemic oxytocin concentration for human sexual behavior? a systematic review. Sex Med. 2021;9(4):100370.
   PubMed Web of Science ®Google Scholar
• Dhanuka I, Simon JA. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Opin Pharmacother. 2015;16(16):2523–2529.
   PubMed Web of Science ®Google Scholar
• Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449‐59.
   Web of Science ®Google Scholar
• Taylor MJ, Rudkin L, Bullemor-Day P, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;5. CD003382.
   PubMedGoogle Scholar
• Clayton AH, Dennerstein L, Pyke R, et al. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Womens Health (Lond). 2010;6(5):639‐53.
   PubMedGoogle Scholar
• Thorp J, Palacios S, Symons J, et al. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG. 2014;121(11):1328‐31.
   Web of Science ®Google Scholar
• DeRogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012;9(4):1074–1085.
   PubMed Web of Science ®Google Scholar
• Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793–804.
   PubMed Web of Science ®Google Scholar
• Jayne C, Simon JA, Taylor LV, et al. Sunflower study investigators. open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180–3188.
   PubMed Web of Science ®Google Scholar
• Katz M, Derogatis L, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–1815.
   PubMed Web of Science ®Google Scholar
• Simon JA, Clayton AH, Kim NN, et al. Clinically meaningful benefit in women with hypoactive sexual desire disorder treated with flibanserin. Sex Med. 2022;10(1):100476.
   PubMed Web of Science ®Google Scholar
• Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the Snowdrop trial. Menopause. 2014;21(6):633–640.
   PubMed Web of Science ®Google Scholar
• Joffe HV, Chang C, Sewell C, et al. FDA approval of flibanserin — treating hypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101–104.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Brown L, Kim NN. Evaluation of safety for flibanserin. Expert Opin Drug Saf. 2020;19(1):1–8.
   PubMed Web of Science ®Google Scholar
• Simon JA, Clayton AH, Kingsberg SA, et al. Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: a randomized, double-blind, crossover study. J Sex Med. 2019;16(11):1779–1786.
   PubMed Web of Science ®Google Scholar
• Millheiser L, Clayton AH, Parish SJ, et al. Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. Sex Med. 2019;7(4):418–424.
   PubMed Web of Science ®Google Scholar
• Simon JA, Clayton AH, Parish SJ, et al. Effects of alcohol administered with flibanserin in healthy premenopausal women: a randomized, double-blind, single-dose crossover study. J Sex Med. 2020;17(1):83–93.
   PubMed Web of Science ®Google Scholar
• Naguib MJ, Makhlouf AIA. Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study. Drug Deliv. 2021;28(1):1301–1311.
   PubMed Web of Science ®Google Scholar
• Dooley EM, Miller MK, Clayton AH. Flibanserin: from bench to bedside. Sex Med Rev. 2017;5(4):461–469.
   PubMed Web of Science ®Google Scholar
• Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–462.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Tiranini L, et al. Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics? Expert Opin Pharmacother. 2018;19(5):421–423.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79(14):1599–1606.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5(4):887–897.
   PubMed Web of Science ®Google Scholar
• Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2021Jan; 18: 1–9 Epub ahead of print
   Google Scholar
• Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health. 2016;12(3):325–337.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908.
   PubMedGoogle Scholar
• Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909–917.
   PubMed Web of Science ®Google Scholar
• Althof S, Derogatis LR, Greenberg S, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226–1235.
   PubMed Web of Science ®Google Scholar
• Mayer D, Lynch SE. Bremelanotide: new drug approved for treating hypoactive sexual desire disorder. Ann Pharmacother. 2020;54(7):684–690.
   PubMed Web of Science ®Google Scholar
• Spielmans GI. Re-analyzing phase iii bremelanotide trials for “hypoactive sexual desire disorder” in women. spielmans Gi. re-analyzing phase iii bremelanotide trials for “hypoactive sexual desire disorder” in women. J Sex Res. 2021;58(9):1085–1105.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Clayton AH, Portman D, et al., Failure of a meta-analysis: a commentary on glen spielmans’s “re-analyzing phase iii bremelanotide trials for ‘hypoactive sexual desire disorder in women’“. J Sex Res. 58(9): 1106–1107. 2021.
   PubMed Web of Science ®Google Scholar
• Koochaki P, Revicki D, Wilson H, et al. the patient experience of premenopausal women treated with bremelanotide for hypoactive sexual desire disorder: reconnect exit study results. J Womens Health (Larchmt). 2021;30(4):587–595.
   PubMed Web of Science ®Google Scholar
• Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Simon JA, Davis SR, et al. International society for the study of women’s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849–867.
   PubMed Web of Science ®Google Scholar
• Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an international menopause society white paper. Climacteric. 2020;23(5):426–446.
   PubMed Web of Science ®Google Scholar
• Achilli C, Pundir J, Ramanathan P, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107(2):475–82.e15.
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Jane F, et al. Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. J Sex Med. 2014;11(3):831–839.
   PubMed Web of Science ®Google Scholar
• Nappi RE. Testosterone for women: green light for sex, amber light for health? Lancet Diabetes Endocrinol. 2019;7(10):738–739.
   PubMed Web of Science ®Google Scholar
• Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9:1134–1148.
   PubMed Web of Science ®Google Scholar
• Jayne CJ, Heard MJ, Zubair S, et al. New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. Int J Womens Health. 2017;9:171–178.
   PubMed Web of Science ®Google Scholar
• Clayton AH, El Haddad S, Iluonakhamhe JP, et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014;13(10):1361–1374.
   PubMed Web of Science ®Google Scholar
• Pyke RE. Trazodone in sexual medicine: underused and overdosed? Sex Med Rev. 2020;8(2):206–216.
   PubMed Web of Science ®Google Scholar
• Croft HA. Understanding the role of serotonin in female hypoactive sexual desire disorder and treatment options. J Sex Med. 2017;14(12):1575–1584.
   PubMed Web of Science ®Google Scholar
• Schoen C, Bachmann G. Sildenafil citrate for female sexual arousal disorder: a future possibility? Nat Rev Urol. 2009;6(4):216–222.
   PubMed Web of Science ®Google Scholar
• Leddy LS, Yang CC, Stuckey BG, et al. Influence of sildenafil on genital engorgement in women with female sexual arousal disorder. J Sex Med. 2012;9(10):2693–2697.
   PubMed Web of Science ®Google Scholar
• Belkin ZR, Krapf JM, Goldstein AT. Drugs in early clinical development for the treatment of female sexual dysfunction. Expert Opin Investig Drugs. 2015;24(2):159–167.
   PubMed Web of Science ®Google Scholar
• Miller MK, Smith JR, Norman JJ, et al. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018;23(3):223–230.
   PubMed Web of Science ®Google Scholar
• West E, Krychman M. Natural aphrodisiacs—a review of selected sexual enhancers. Sex Med Rev. 2015;3(4):279–288.
   PubMedGoogle Scholar
• Sha’ari N, Woon LS, Sidi H, et al. Beneficial effects of natural products on female sexual dysfunction: a systematic review and meta-analysis. Phytomedicine. 2021;93:153760.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Goldstein I, Kim NN, et al. The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467–487.
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15(4):661–666.
   PubMed Web of Science ®Google Scholar
• Particco M, Djumaeva S, Nappi RE, et al. The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. Menopause. 2020;27(4):423–429.
   PubMed Web of Science ®Google Scholar
• Nappi PRE, Cucinella L, Martella S, et al. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. 2016;94:87–91.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L. Sexuality, pelvic floor/vaginal health and contraception at menopause. Best Pract Res Clin Obstet Gynaecol. 2021 Nov 15. S1521-6934(21)00170-X. doi:10.1016/j.bpobgyn.2021.11.006
   Google Scholar
• Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martini E, et al. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause – systematic review. Maturitas. 2022;156:37–59.
   PubMed Web of Science ®Google Scholar
• Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381–1389.
   PubMed Web of Science ®Google Scholar
• Both S. Recent developments in psychopharmaceutical approaches to treating female sexual interest and arousal disorder. Curr Sex Health Rep. 2017;9(4):192–199.
   PubMedGoogle Scholar
• Höhle D, van Rooij K, Bloemers J, et al. A survival of the fittest strategy for the selection of genotypes by which drug responders and non-responders can be predicted in small groups. PLoS One. 2021;16(3):e0246828.
   PubMed Web of Science ®Google Scholar
• Tuiten A, Michiels F, Böcker KB, et al. Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: a double-blind, randomized, placebo-controlled cross-over trial. Womens Health (Lond). 2018;14:1745506518788970.
   Google Scholar
• Pyke RE, Clayton AH. Dose-finding study of lorexys for hypoactive sexual desire disorder in premenopausal women. J Sex Med. 2019;16(12):1885–1894.
   PubMed Web of Science ®Google Scholar
• Andreev-Andrievskiy A, Lomonosov M, Popova A, et al. BP101 peptide promotes female sexual receptivity in the rat. J Sex Med. 2017;14(3):336–346.
   PubMed Web of Science ®Google Scholar
• Behnia B, Heinrichs M, Bergmann W, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav. 2014;65(3):308–318.
   PubMed Web of Science ®Google Scholar
• Muin DA, Wolzt M, Marculescu R, et al. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril. 2015;104(3):715–23.e4.
   PubMed Web of Science ®Google Scholar
• Zohrabi I, Abedi P, Ansari S, et al. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial. BMC Womens Health. 2020;20(1):108.2.
   PubMed Web of Science ®Google Scholar
• Krychman M, Millheiser LS. Sexual health issues in women with cancer. J Sex Med. 2013;10(Suppl 1):5–15.
   PubMedGoogle Scholar
• Morin M, Carroll MS, Bergeron S. Systematic review of the effectiveness of physical therapy modalities in women with provoked vestibulodynia. Sex Med Rev. 2017 Jul;5(3):295–322.
   PubMed Web of Science ®Google Scholar
• Cyr M-P, Dumoulin C, Bessette P, et al. A prospective single-arm study evaluating the effects of a multimodal physical therapy intervention on psychosexual outcomes in women with dyspareunia after gynecologic cancer. J Sex Med. 2021;18(5):946–954.
   PubMed Web of Science ®Google Scholar
• Padoa A, McLean L, Morin M, et al. The Overactive Pelvic Floor (OPF) and sexual dysfunction. part 2: evaluation and treatment of sexual dysfunction in OPF patients. Sex Med Rev. 2021;9(1):76–92.
   PubMed Web of Science ®Google Scholar
• Brotto LA, Zdaniuk B, Rietchel L, et al. Moderators of improvement from mindfulness-based vs traditional cognitive behavioral therapy for the treatment of provoked Vestibulodynia. J Sex Med. 2020;17(11):2247–2259.
   PubMed Web of Science ®Google Scholar
• Rosen NO, Dawson SJ, Brooks M, et al. Treatment of Vulvodynia: pharmacological and non-pharmacological approaches. Drugs. 2019;79(5):483–493.
   PubMed Web of Science ®Google Scholar
• Haraldson P, Mühlrad H, Heddini U, et al. Botulinum toxin a as a treatment for provoked vestibulodynia: a randomized controlled trial. Obstet Gynecol. 2020 Sep;136(3):524–532.
   PubMedGoogle Scholar
• Morin M, Dumoulin C, Bergeron S, et al. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a multicenter, randomized trial. Am J Obstet Gynecol. 2021;224(2):189.e1–189.e12. PVD Study Group.
   PubMed Web of Science ®Google Scholar
• Mercier J, Morin M, Tang A, et al. Pelvic floor muscle training: mechanisms of action for the improvement of genitourinary syndrome of menopause. Climacteric. 2020;23(5):468–473.
   PubMed Web of Science ®Google Scholar